drugset / Trial / NCT02011022

Pharmacokinetic Analysis of High Dose Methotrexate in Pediatric Lymphoblastic Malignancies

NCT02011022

Non-randomizedParallel-groupOpen-label

Summary

\* The pharmacokinetics of MTX were assessed with regards to the relevance of several different patient specific factors in 291 pediatric patients, who were administered with high dose of MTX. Population pharmacokinetics of MTX analysis was performed by using nonlinear mixed effects modeling.

Timeline

Start
2009-05
Primary completion
2009-12
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 3 mg/m2
Subject Methotrexate Small molecule 5 mg/m2

Indications